US 12,105,090

Application 16/211,154 · Granted Oct 1, 2024

Methods of treating a multiple sclerosis patient with anti-vla-4 therapy

Estimated expiration

May 31, 2032

5y 192d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
May 31, 2012
+ 20 years
May 31, 2032
PTA +751d
Jun 21, 2034
TD cap (US 12,066,442)
May 31, 2032
Final
May 31, 2032

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
December 5, 2018
Earliest effective filing
May 31, 2012
Issue date
October 1, 2024
PTA
+751 days
Base expiry (before PTA)
May 31, 2032

May 31, 2012 + 20 years = May 31, 2032 + 751 PTA days = June 21, 2034

  • Continuation of application 14/122,754, filed Jun 23, 2014
  • National stage entry of application PCTUS2012040283, filed May 31, 2012
  • National stage entry of application PCTUS2012040283, filed May 31, 2012
  • PRO61/550,257 — Provisional — not used for base term
  • PRO61/491,810 — Provisional — not used for base term
  • PRO61/508,584 — Provisional — not used for base term
  • PRO61/636,588 — Provisional — not used for base term
  • PRO61/491,810 — Provisional — not used for base term
  • PRO61/508,584 — Provisional — not used for base term
  • PRO61/550,257 — Provisional — not used for base term
  • PRO61/636,588 — Provisional — not used for base term
  • PRO61/491,810 — Provisional — not used for base term
  • PRO61/508,584 — Provisional — not used for base term
  • PRO61/550,257 — Provisional — not used for base term
  • PRO61/636,588 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to May 31, 2032 (earliest expiring referenced patent: US 12,066,442)

  • US 12,105,090· Application 16/211,154(from application 16/211,154)Capping patent

    Methods of treating a multiple sclerosis patient with anti-vla-4 therapy

    Filing date
    Dec 5, 2018
    Earliest effective filing
    May 31, 2012
    Issue date
    Oct 1, 2024
    PTA
    +751 days
    Calculated expiration
    Jun 21, 2034

    Continuation of 14/122,754, filed Jun 23, 2014

    National stage entry of PCTUS2012040283, filed May 31, 2012

    National stage entry of PCTUS2012040283, filed May 31, 2012

    May 31, 2012 + 20y + 751d PTA = Jun 21, 2034

  • US 12,066,442· Application 17/393,335(from application 17/393,335)Capping patent

    Method of assessing risk of pml

    Filing date
    Aug 3, 2021
    Earliest effective filing
    May 31, 2012
    Issue date
    Aug 20, 2024
    PTA
    0 days
    Calculated expiration
    May 31, 2032

    Divisional of 16/211,154, filed Dec 5, 2018, issued as US 12,105,090

    Continuation of 14/122,754, filed Jun 23, 2014

    National stage entry of PCTUS2012040283, filed May 31, 2012

    National stage entry of PCTUS2012040283, filed May 31, 2012

    Continuation of 14/122,754, filed Jun 23, 2014

    National stage entry of PCTUS2012040283, filed May 31, 2012

    May 31, 2012 + 20y = May 31, 2032

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 16/211,154 · US 12,105,090

PatentReply compiles the prosecution history behind US 12,105,090: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12105090

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.